Electronic Supplementary Information (ESI)

Effective loading of cisplatin into a nanoscale UiO-66 metal-organic

framework with preformed defects⁺

Shi-Xin Lin,^a Wei-Lun Pan,^b Ru-Jie Niu,^a Yan-Liu,^a Jin-Xiang Chen,^{*b} Wen-Hua Zhang,^{*a}

Jian-Ping Lang*^a and David J. Young^c

^a College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou

215123, China. Email: whzhang@suda.edu.cn; jplang@suda.edu.cn

^b Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences,

Southern Medical University, Guangzhou 510515, China. Email: jxchen@smu.edu.cn

^c College of Engineering, Information Technology & Environment, Charles Darwin University, Darwin,

Northern Territory 0810, Australia

Contents

Scheme S1 Synthetic strategies and for loading cisplatin into UiO-66. The second strategy was
halted because of difficulties encountered in preparing the cisplatin precursor2
Fig. S1 TGA curves of UiO-66-350 (black) and UiO-66-TFA (red)3
Fig. S2 FT-IR spectra of UiO-66-350-PA (red) and UiO-66-350-PA-Pt (blue)
Fig. S3 EDX spectrum of UiO-66-350-PA-Pt
Fig. S4 UV-Vis spectra for release of cisplatin at different times4
Fig. S5 Agarose GE patterns for P-DNA loading into UiO-66-350-PA-Pt. Lane 1-7 DNA (50 nM) with
UiO-66-350-PA-Pt at the concentrations of 5.4, 10.8, 27.0, 54.0, 162.0, 324.0 and 486.0 $\mu\text{M},$
respectively, Lane 8: DNA marker4
Table S1 The ICP analysis show the concentration of the elements in UiO-66-350-PA-Pt (the ratio
of Zr : Pt : P is 9 : 1 : 1 corresponding to the Zr ₆ : Pt : P being 1.5 : 1 : 1)5
Table S2 BET surface area (SBET) and total pore volume (Vp) of UiO-66-TFA, UiO-66-350, UiO-66-350-
PA and UiO-66-350-PA-Pt5
Table S3 The ICP analysis showing the concentration of platinum at intervals after release. C_1 is the
concentration after dilution of C ₂ (the actual concentration) by 25 times5



Scheme S1 Synthetic strategies and for loading cisplatin into UiO-66. The second strategy was halted because of difficulties encountered in preparing the cisplatin precursor.



Fig. S1 TGA curves of UiO-66-350 (black) and UiO-66-TFA (red).



Fig. S2 FT-IR spectra of UiO-66-350-PA (red) and UiO-66-350-PA-Pt (blue).



Fig. S3 EDX spectrum of UiO-66-350-PA-Pt.



Fig. S4 UV-Vis spectra for release of cisplatin at different times.



Fig. S5 Agarose GE patterns for P-DNA loading into UiO-66-350-PA-Pt. Lane 1-7 DNA (50 nM) with UiO-66-350-PA-Pt at the concentrations of 5.4, 10.8, 27.0, 54.0, 162.0, 324.0 and 486.0 μ M, respectively, Lane 8: DNA marker.

 Element
 Cv (mg/L)
 Cd (mmol/L)

 Zr
 95.12
 1.04

 Pt
 21.88
 0.11

 P
 3.490
 0.11

Table S1 The ICP analysis show the concentration of the elements in UiO-66-350-PA-Pt (the ratio of Zr : Pt : P is 9 : 1 : 1 corresponding to the $Zr_6 : Pt : P$ being 1.5 : 1 : 1).

Table S2 BET surface area (S_{BET}) and total pore volume (V_p) of UiO-66-TFA, UiO-66-350, UiO-66-350-PA and UiO-66-350-PA-Pt.

Samples	S _{BET} (m ² g ⁻¹)	V _P (cm³g⁻¹)
UiO-66-TFA	1368	0.6246
UiO-66-350	1000	0.5433
UiO-66-350-PA	746	0.4460
UiO-66-350-PA-Pt	552	0.4044

Table S3 The ICP analysis showing the concentration of platinum at intervals after release. C_1 is theconcentration after dilution of C_2 (the actual concentration) by 25 times.

Samples	C1 (mg/L)	C ₂ (mg/L)
1h	2.99	74.75
2h	3.64	91.00
4h	3.73	93.25
6h	3.84	96.00
8h	3.91	97.75
10h	4.14	106.00
240h	4.38	109.50